Could T-cells be a gamechanger in the fight against COVID-19?

A letter signed by more than 60 biotech and academic leaders was sent last month to the FDA urging the inclusion of a recommendation for T-cell assessment in Covid-19 vaccine clinical trials, with the aim of comprehensively measuring immune response more effectively.

The suggested research into T-cells would look more closely at evidence from studies into the vaccine response in humans that shows while antibodies protect and provide a barrier from virus getting in, T-cells can protect from progression to severe disease. 

While antibodies are easy to measure, the letter outlines that the measurement of T-cell responses alongside them, can help better determine and evaluate the efficacy of vaccines and thus aid decisions regarding protection against Covid-19 both now and in the future.

The letter notes that there is a limited study on T-cells in SARS-CoV-2 research that's slowing further research and policy information on emerging variants and long-term protection against them.

It states that “Examining the T-cell response has applications for clinical diagnosis and management, evaluation of protective immunity and vaccine assessment.”

There is still so much more to learn about COVID-19, as proven by the emergence of the Omicron variant. Looking more closely into the T-cell response, while more labour intensive, could, in future, inform public and personal health decisions about how people are protected against the disease, at both public and personal levels.

Back to the list